More about post-transplant cyclophosphamide in haploidentical grafts: full or reduced doses?

References

• Malard F, Chevallier P, Guillaume T, et al. Continuous reduced nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: A single-institution’s three decade experience. Biol Blood Marrow Transplant. 2014;20(8):1217–1223. doi:10.1016/j.bbmt.2014.04.021
   PubMed Web of Science ®Google Scholar
• Passweg JR, Baldomero H, Chabannon C, et al. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplant. 2021;56(7):1651–1664. doi:10.1038/s41409-021-01227-8
   PubMed Web of Science ®Google Scholar
• Luznik L, O’Donnell PV, Symons HJ, et al. HLA-Haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641–650. doi:10.1016/j.bbmt.2008.03.005
   PubMed Web of Science ®Google Scholar
• Jaime-Pérez JC, Salazar-Cavazos L, Aguilar-Calderón P, et al. Assessing the efficacy of an ambulatory peripheral blood hematopoietic stem cell transplant program using reduced intensity conditioning in a low-middle-income country. Bone Marrow Transplant. 2019;54(6):828–838. doi:10.1038/s41409-018-0338-7
   PubMed Web of Science ®Google Scholar
• Mussetti A, Paviglianiti A, Parody R, et al. Is post-transplant cyclophosphamide the new methotrexate? J Clin Med. 2021;10(16):3548, doi:10.3390/jcm10163548
   PubMed Web of Science ®Google Scholar
• Russo A, Oliveira G, Berglund S, et al. NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. Blood. 2018;131(2):247–262. doi:10.1182/blood-2017-05-780668
   PubMed Web of Science ®Google Scholar
• Raiola AM, Dominietto A, Ghiso A, et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant. 2013;19(1):117–122. doi:10.1016/j.bbmt.2012.08.014
   PubMed Web of Science ®Google Scholar
• Xu ZL, Xu LP, Zhang YY, et al. Incidence and predictors of severe cardiotoxicity in patients with severe aplastic anaemia after haploidentical haematopoietic stem cell transplantation. Bone Marrow Transplant. 2019;54(10):1694–1700. doi:10.1038/s41409-019-0509-1
   PubMed Web of Science ®Google Scholar
• Ruggeri A, Roth-Guepin G, Battipaglia G, et al. Incidence and risk factors for hemorrhagic cystitis in unmanipulated haploidentical transplant recipients. Transpl Infect Dis. 2015;17(6):822–830. doi:10.1111/tid.12455
   PubMed Web of Science ®Google Scholar
• Ponticelli C, Escoli R, Moroni G. Does cyclophosphamide still play a role in glomerular diseases? Autoimmun Rev. 2018;17(10):1022–1027. doi:10.1016/j.autrev.2018.04.007
   PubMed Web of Science ®Google Scholar
• Murrieta-Álvarez I, Ruiz-Argüelles GJ. Bien plus encore: haplos indeed can be completed on an outpatient basis. Transplant Cell Ther. 2021;27(6):519–520. doi:10.1016/j.jtct.2021.03.009
   PubMedGoogle Scholar
• Colunga-Pedraza PR, Gómez-De León A, Rodríguez-Roque CS, et al. Outpatient haploidentical stem cell transplantation using post-transplant cyclophosphamide Is safe and feasible. Transplant Cell Ther. 2021;27(3):259.e1–259.e6.
   PubMedGoogle Scholar
• Ruiz-Argüelles GJ, Seber A, Ruiz-Delgado GJ. Conducting hematopoietic stem cell transplantation in low and middle income countries. Hematology. 2022;27(1):809–812. doi:10.1080/16078454.2022.2105513
   PubMed Web of Science ®Google Scholar
• González-Llano O, González-López EE, Ramírez-Cázares AC, et al. Haploidentical peripheral blood stem cell transplantation with posttransplant cyclophosphamide in children and adolescents with hematological malignancies: González-Llano et al. Pediatr Blood Cancer. 2016;63(11):2033–2037. doi:10.1002/pbc.26131
   PubMed Web of Science ®Google Scholar
• Olivares-Gazca JC, Pastelín-Martínez MDL, Montes-Robles MA, et al. Can doses of post-transplantation cyclophosphamide in haploidentical stem cell allografts be reduced? Hematology. 2023;28(1):2242176, doi:10.1080/16078454.2023.2242176
   PubMed Web of Science ®Google Scholar
• Ruiz-Delgado GJ, Ruiz-Argüelles GJ. A Mexican way to cope with stem cell grafting. Hematology. 2012;17(suppl1):s195–s197. doi:10.1179/102453312X13336169157130
   PubMedGoogle Scholar
• Kato K, Takeuchi A, Akashi K, et al. Cyclophosphamide-induced tolerance in allogeneic transplantation: from basic studies to clinical application. Front Immunol. 2020;10:3138, doi:10.3389/fimmu.2019.03138
   PubMed Web of Science ®Google Scholar
• Duléry R, Bastos J, Paviglianiti A, et al. Thiotepa, busulfan, and fludarabine conditioning regimen in T cell-replete HLA-haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019;25(7):1407–1415. doi:10.1016/j.bbmt.2019.02.025
   PubMed Web of Science ®Google Scholar
• Lin R, Wang Y, Huang F, et al. Two dose levels of rabbit antithymocyte globulin as graft-versus-host disease prophylaxis in haploidentical stem cell transplantation: a multicenter randomized study. BMC Med. 2019;17(1):156, doi:10.1186/s12916-019-1393-7
   PubMed Web of Science ®Google Scholar
• Huang Z, Yan H, Teng Y, et al. Lower dose of ATG combined with basiliximab for haploidentical hematopoietic stem cell transplantation is associated with effective control of GVHD and less CMV viremia. Front Immunol. 2022;13:1017850, doi:10.3389/fimmu.2022.1017850
   PubMed Web of Science ®Google Scholar
• Cesaro S, Crocchiolo R, Tridello G, et al. Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT. Bone Marrow Transplant. 2018;53(4):422–430. doi:10.1038/s41409-017-0016-1
   PubMed Web of Science ®Google Scholar
• Sugita J, Kamimura T, Ishikawa T, et al. Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation. Bone Marrow Transplant. 2021;56(3):596–604. doi:10.1038/s41409-020-01065-0
   PubMed Web of Science ®Google Scholar
• Duléry R, Goudet C, Mannina D, et al. Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies. Bone Marrow Transplant. 2023;58(4):386–392. doi:10.1038/s41409-022-01908-y
   PubMed Web of Science ®Google Scholar
• Duléry R, Malard F, Brissot E, et al. (2023). Reduced post-transplant cyclophosphamide dose with antithymocyte globulin in peripheral blood stem cell haploidentical transplantation. Bone Marrow Transplant [Internet]. https://www.nature.com/articles/s41409-023-02085-2.
   Google Scholar